| Today’s Big NewsFeb 29, 2024 |
| By Max Bayer Novo Nordisk executives unveiled the company's U.S. R&D hub on Wednesday, repurposing Dicerna's old headquarters as the new regional outpost. The event comes as Novo's R&D investments are skyrocketing, thanks to the revenue flooding in from the metabolic franchise. |
|
|
|
By Annalee Armstrong In 2022, Kineta swooped in to rescue Yumanity’s immunotherapy from the scrapheap. Now, Kineta needs some rescuing itself. After a strategic review, the small oncology biotech is conducting a corporate restructuring and reducing its workforce by 64%. |
By Annalee Armstrong After two years, CytoDyn’s HIV program is finally free of the FDA clinical hold. In a short update Thursday, CEO Jacob Lalezari, M.D., heralded the lifting of the hold as a “new chapter” for lead asset leronlimab. |
Sponsored by The Dedham Group The influence of oncology pathways is growing. Here are the challenges and opportunities for biopharma companies in the clinical pathways landscape. |
|
March 18-20, 2024 | Savannah, GA The Fierce TMF Summit is the must-attend event for clinical document management professionals to learn, network and connect. Gain invaluable insights from unique case studies, panels, and workshops, and access the best networking the industry has to offer. Sign Up Today!
|
|
By Annalee Armstrong The first signs of spring are beginning to emerge and so too are the shoots of the next biotech from drug designer J. Jean Cui, Ph.D. BlossomHill Therapeutics has raised $100 million in a series B financing, bringing the company’s total fundraising to $173 million so far. |
Sponsored by Sengenics Revolutionizing Cancer Detection: The Power of Autoantibodies |
By Nick Paul Taylor Ironwood Pharmaceuticals’ $1 billion short bowel syndrome bet has delivered a phase 3 win—and wiped 30% off the company’s share price. While the study met its primary endpoint, the results failed to convince investors it can win out over Takeda’s Gattex, its potential generic copies and Zealand Pharma’s glepaglutide. |
Sponsored by ICON In this exclusive interview, ICON Biotech President Chris Smyth paints a picture of the operating environment facing biotechs in 2024. |
By Gabrielle Masson,Annalee Armstrong,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Angus Liu Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry. But a new funding pact between Carlyle’s Abingworth and Gilead Sciences is somewhat unconventional. |
By Helen Floersh Oncology CRO Sarah Cannon Research Institute, or SCRI, has struck a deal with AstraZeneca to optimize the pharmaceutical giant’s cancer clinical trials in the U.S. |
By Nick Paul Taylor Biotechs face a core communication challenge. How, in an industry that can spawn hundreds of startups every year, can you connect with the talent and investors who are integral to your prospects? Belharra Therapeutics has come up with an atypical answer to that question: podcasts. |
By Andrea Park Shortly after signing off on the first human trial of Neuralink’s brain-computer interface system last year, the FDA reportedly discovered a handful of quality control issues related to the Elon Musk-founded company’s animal experiments of the technology, according to Reuters. |
By Noah Tong A new study in Diabetes Therapy from Virta Health says the company's carbohydrate restricted nutrition therapy allows patients who no longer want a GLP-1 prescription to still keep the weight off. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we explore the impact of environmental, social, and governance measures, commonly known as ESG, on the pharmaceutical industry. Fierce Pharma's Fraiser Kansteiner engages in a conversation with Jim Greffet, Head of ESG Strategy at Eli Lilly, to gain insights and discuss Lilly's specific ESG initiatives. |
|
|---|
|
|
|
Thursday, March 7, 2024 | 1pm ET / 10am PT Join us for this timely look at the critical role a CDMO’s process development approach can play in shortening development timelines for biotherapeutics. Gain key insights on risk-mitigation strategies, utilizing flexible development platforms, optimizing integration, managing process development, and more. Register now.
|
|
| Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
